UK alarm bells are ringing as a biotech cuts a few trial sites, fretting over Brexit’s impact on drug development

A very low-profile transatlantic biotech has found a place in the spotlight for the first time with its decision to cut UK trial sites out of an upcoming heart drug study — evidently due to uncertainty about drug development in a post-Brexit world.